The use of artesunate-pyronaridine for the treatment of uncomplicated malaria: Information note

The use of artesunate-pyronaridine for the treatment of uncomplicated malaria

This note aims to clarify any perceived contradiction between the inclusion of artesunate-pyronaridine in the WHO list of prequalified medicines for malaria and Model List of Essential Medicines, and the recommendations in the current WHO Guidelines for the treatment of malaria (2015).

Considering recent positive scientific opinion, artesunate-pyronaridine can be considered a safe and efficacious artemisinin-based combination therapy for the treatment of uncomplicated malaria in adults and children weighing 5 kg and over in all malaria-endemic areas. Countries can consider including this medicine in their national treatment guidelines, procure it, and monitor its safety and efficacy. Deployment should be conducted under a pharmacovigilance system as required for the introduction of all new medicines.